CAS: 532-43-4; 3-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)-5-(2-Hydroxyethyl)-4-Methylthiazol-3-Ium Nitrate

上下游产品

H-thiazole-2-thione3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-3H-thiazole-2-thione Thiamine hydr°Chloride Aneurin thiamine sulfate

硫胺素置于双氧水,硝酸体系中,用 水 作为反应溶剂,化学反应生成 硝酸硫胺
参考文献:一种硝酸硫胺块状晶体产品的制备方法
标题:一种硝酸硫胺块状晶体产品的制备方法
摘要:本发明公开了一种制备硝酸硫胺块状晶体的制备方法.将硫代硫胺固体加入到ph=2~6的酸性蒸馏水中,搅拌作用下向其中滴加质量分数为双氧水,反应,氧化并脱色后得到硫酸硫胺溶液;向上述氧化反应得到的溶液中加入40~60Wt%的硝酸铵溶液,并加入添加剂,搅拌混合.用氨水调节ph至3.9~4.3时,加入硝酸硫胺晶种,养晶0.5~2H,继续调节ph=6.80~7.05,随后以0.5oc/min的速率降温至5oc.过滤,洗涤,干燥得到硝酸硫胺晶体.产品为块状晶体,其长宽比为1:1~4:1,堆密度为0.80~0.93G/ml,休止角为25°~38°,流动性较好,晶体性质显著提高.该制备工艺简单,易于进行工业化.

专利信息

专利号:US-2023091651-A1
优先权日:2021-09-20
标 题:Dietary supplement and method for synthesis of same
发明人：WYNN JASON R
权利人:StrongCell LLC
摘要:A dietary supplement and method for synthesis of the same are disclosed. In one embodiment of the method, an NADH component is provided that includes at least partially microencapsulated nicotinamide having nicotinamide blended with water. A supplement component, such as collagen, coenzyme Q10, vitamins, and minerals, is provided. A mixed component, which is a liquid, is formed by mixing the NADH component with the supplement component at ambient conditions. The mixed component is subjected to a fill production process.

专利号:US-2023089537-A1
优先权日:2021-09-20
标题:Dietary supplement and method for synthesis of same
发明人：WYNN JASON R
权利人:StrongCell LLC
摘要:A dietary supplement and method for synthesis of the same are disclosed. In one embodiment of the method, an NADH component is provided which includes NADH from about 0.1% to about 0.5% blended with water from about 40% to about 84% both by weight of the dietary supplement. A supplement component from about 9% to about 99% by weight of the dietary supplement is also provided. The supplement component may include collagen in about 2% to about 10%, vitamins in about 0.00001% to about 3%, and minerals in about 0.000002% to about 0.5% all by weight of the dietary supplement. A mixed component is formed by mixing the NADH component with the supplement component at ambient conditions. The mixed component is a liquid at ambient conditions having a pH of less than 4.0. The mixed component is subjected to a cold fill production process.

专利号:US-8722384-B2
优先权日:1997-04-11
标 题:Methods and compositions for synthesis of long chain polyunsaturated fatty acids
发明人：KNUTZON DEBORAH; MUKERJI PRADIP; HUANG YUNG-SHENG; THURMOND JENNIFER; CHAUDHARY SUNITA; LEONARD AMANDA EUN-YEONG
权利人:KNUTZON DEBORAH; MUKERJI PRADIP; HUANG YUNG-SHENG; THURMOND JENNIFER; CHAUDHARY SUNITA; LEONARD AMANDA EUN-YEONG; CALGENE LLC; ABBOTT LAB
摘要:The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to γ-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.

专利号:US-7745694-B1
优先权日:1997-04-11
标 题:Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
发明人：KNUTZON DEBORAH; MUKERJI PRADIP; HUANG YUNG-SHENG; THURMOND JENNIFER; CHAUDHARY SUNITA; LEONARD AMANDA EUN-YEONG
权利人:MONSANTO TECHNOLOGY LLC
摘要:The present invention relates to compositions and methods for preparing polyunsaturated long chain fatty acids in plants, plant parts and plant cells, such as leaves, roots, fruits and seeds. Nucleic acid sequences and constructs encoding fatty acid desaturases, including Δ5-desaturases, Δ6-desaturases and Δ12-desaturases, are used to generate transgenic plants, plant parts and cells which contain and express one or more transgenes encoding one or more desaturases. Expression of the desaturases with different substrate specificities in the plant system permit the large scale production of polyunsaturated long chain fatty acids such as docosahexaenoic acid, eicosapentaenoic acid, α-linolenic acid, gamma-linolenic acid, arachidonic acid and the like for modification of the fatty acid profile of plants, plant parts and tissues. Manipulation of the fatty acid profiles allows for the production of commercial quantities of novel plant oils and products.

专利号:EP-1598422-B1
优先权日:1997-04-11
标 题:Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
发明人：KNUTZON DEBORAH; MUKERJI PRADIP; HUANG YUNG-SHENG; THURMOND JENNIFER; CHAUDHARY SUNITA; LEONARD AMANDA EUN-YEONG
权利人:CALGENE LLC; ABBOTT LAB
摘要:Nucleic acid construct contains: (a) at least one of 1617 (S1), 1488 (S2) and 1488 (S3) bp sequences (I), or (b) any sequence encoding the same proteins as (I), coupled to a heterologous sequence, particularly an expression control sequence functional in plants. Also new are: (A) recombinant plant cells containing at least one DNA encoding a Mortierella alpina fatty acid desaturase (FAD), so that it can produce a polyunsaturated fatty acid (PUFA); (B) oils produced by these cells (or plants containing them), and (C) 7 sequences encoding human FAD and two sequences encoding Schizochytrium FAD, when expressed in plant cells.

专利号:US-2005282781-A1
优先权日:2004-06-18
标 题 :Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
发明人：GHOSAL SHIBNATH
权利人:GHOSAL SHIBNATH
摘要:An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C 20:5n-3 (and C 22:6 n-3 ) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.